| 000 | 01642 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514162541.0 | ||
| 264 | 0 | _c20031125 | |
| 008 | 200311s 0 0 eng d | ||
| 022 | _a1533-4406 | ||
| 024 | 7 |
_a10.1056/NEJMoa030002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLebwohl, Mark | |
| 245 | 0 | 0 |
_aA novel targeted T-cell modulator, efalizumab, for plaque psoriasis. _h[electronic resource] |
| 260 |
_bThe New England journal of medicine _cNov 2003 |
||
| 300 |
_a2004-13 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aCD11a Antigen |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPsoriasis _xclassification |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 700 | 1 | _aTyring, Stephen K | |
| 700 | 1 | _aHamilton, Tiffani K | |
| 700 | 1 | _aToth, Darryl | |
| 700 | 1 | _aGlazer, Scott | |
| 700 | 1 | _aTawfik, Naji H | |
| 700 | 1 | _aWalicke, Patricia | |
| 700 | 1 | _aDummer, Wolfgang | |
| 700 | 1 | _aWang, Xiaolin | |
| 700 | 1 | _aGarovoy, Marvin R | |
| 700 | 1 | _aPariser, David | |
| 773 | 0 |
_tThe New England journal of medicine _gvol. 349 _gno. 21 _gp. 2004-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1056/NEJMoa030002 _zAvailable from publisher's website |
| 999 |
_c14364356 _d14364356 |
||